ADDITIONAL FILE 1

Table of contents

Table S1. Distribution of comorbidity status among confirmed cases in Quebec adults ........................................... 2
Table S2. STROBE Statement—Checklist of items that should be included in reports of cross-sectional studies .................. 3
Table S3. Classifications of active physical comorbidities .................................................................................................. 5
Table S4. Sample size calculations .................................................................................................................................. 6
Table S5. Key socio-demographic characteristics of participants, by period ................................................................. 7
Table S6. Time trends in the mean number of social contacts of individuals with and without active physical comorbidities .......................................................................................................................................... 9
Table S7. Time trends in the mean total number of social contacts of individuals with and without active physical comorbidities at risk of COVID-19 complications .............................................................................................................. 12
Table S8. Vaccination coverage with one dose of individuals with and without active physical comorbidities in the third wave ............................................................................................................................................ 14
Table S9. Recommended Quebec priority groups for vaccination against COVID-19 .......................................................... 15
Table S10. Mean total number of social contacts in the third wave of individuals with and without active physical comorbidities according to vaccination status with one dose .......................................................................................................................... 16
Figure S1. Distribution of participants according to classifications of comorbidities ................................................................. 17
Figure S2. Time trends in vaccination coverage with one dose of individuals with and without active physical comorbidities in the third wave ........................................................................................................................................... 18
Example of questions S1. Questions on health conditions .................................................................................................. 19
Example of questions S2. Example of the social contact diary ................................................................................................. 21
# Table S1. Distribution of comorbidity status among confirmed cases in Quebec adults*

| Age Group          | Without comorbidities | With comorbidities |
|--------------------|-----------------------|--------------------|
|                    | n        | %  | n        | %  | n        | %  |
| All adults         |          |    |          |    |          |    |
| Without comorbidities | 19265 | 51.2 | 94879 | 56.6 | 29710 | 62.3 |
| With comorbidities  | 18331 | 48.8 | 72634 | 43.4 | 17997 | 37.7 |
| 18-45 years old    |          |    |          |    |          |    |
| Without comorbidities | 12529 | 71.0 | 64201 | 73.6 | 20491 | 75.3 |
| With comorbidities  | 5119  | 29.0 | 23064 | 26.4 | 6715  | 24.7 |
| 46-65 years old    |          |    |          |    |          |    |
| Without comorbidities | 6169  | 47.3 | 27159 | 50.3 | 8303  | 52.9 |
| With comorbidities  | 6877  | 52.7 | 26846 | 49.7 | 7386  | 47.1 |
| 66-75 years old    |          |    |          |    |          |    |
| Without comorbidities | 416   | 17.9 | 2609  | 22.9 | 722   | 25.3 |
| With comorbidities  | 1914  | 82.1 | 8787  | 77.1 | 2128  | 74.7 |
| >75 years old      |          |    |          |    |          |    |
| Without comorbidities | 151   | 3.3  | 910   | 6.1  | 194   | 9.9  |
| With comorbidities  | 4421  | 96.7 | 13937 | 93.9 | 1768  | 90.1 |

* Cases from nursing homes are excluded.

Methodology used to generate data from the first wave is available online [6]. The same methodology has been used for the other waves.
Table S2. STROBE Statement—Checklist of items that should be included in reports of cross-sectional studies [30]

| Item No | Recommendation | Page No |
|---------|----------------|---------|
| Title and abstract | 1 | (a) Indicate the study’s design with a commonly used term in the title or the abstract | 2 |
| | | (b) Provide in the abstract an informative and balanced summary of what was done and what was found | 2, 3 |
| Introduction | 2 | Explain the scientific background and rationale for the investigation being reported | 4, 5 |
| Objectives | 3 | State specific objectives, including any prespecified hypotheses | 5, 6 |
| Methods | 4 | Present key elements of study design early in the paper | 6 |
| Study design | 5 | Describe the setting, locations, and relevant dates, including periods of recruitment, exposure, follow-up, and data collection | 6, 7, 8, 9 Figure 1 |
| Setting | 6 | (a) Give the eligibility criteria, and the sources and methods of selection of participants | 6 |
| Participants | 7 | Clearly define all outcomes, exposures, predictors, potential confounders, and effect modifiers. Give diagnostic criteria, if applicable | 7, 8, 9, 10 |
| Variables | 8* | For each variable of interest, give sources of data and details of methods of assessment (measurement). Describe comparability of assessment methods if there is more than one group | 7, 8, 9 |
| Data sources/measurement | 9 | Describe any efforts to address potential sources of bias | 9, 10 |
| Bias | 10 | Explain how the study size was arrived at | 10 |
| Study size | 11 | Explain how quantitative variables were handled in the analyses. If applicable, describe which groupings were chosen and why | 9, 10 |
| Quantitative variables | 12 | (a) Describe all statistical methods, including those used to control for confounding | 9, 10 |
| Statistical methods | | (b) Describe any methods used to examine subgroups and interactions | 9, 10 |
| | | (c) Explain how missing data were addressed | 9 |
| | | (d) If applicable, describe analytical methods taking account of sampling strategy | N/A |
| | | (e) Describe any sensitivity analyses | 10 Appendix p.5 |
| Results | 13* | (a) Report numbers of individuals at each stage of study—eg numbers potentially eligible, examined for eligibility, confirmed eligible, included in the study, completing follow-up, and analysed | 10 Appendix p.17 |
| Participants | | (b) Give reasons for non-participation at each stage | 10 |
| Item No | Recommendation | Page No |
|---------|----------------|---------|
|         | (c) Consider use of a flow diagram | N/A |
| Descriptive data | 14* | (a) Give characteristics of study participants (eg demographic, clinical, social) and information on exposures and potential confounders | 10, 11 Table 1 Appendix p.7, 8, 17 |
|         | | (b) Indicate number of participants with missing data for each variable of interest | 10 |
| Outcome data | 15* | Report numbers of outcome events or summary measures | 11, 12, 13 Figure 2, 3, 4 |
| Main results | 16 | (a) Give unadjusted estimates and, if applicable, confounder-adjusted estimates and their precision (eg, 95% confidence interval). Make clear which confounders were adjusted for and why they were included | 11, 12, 13 Appendix p.9, 10, 11 |
|         | | (b) Report category boundaries when continuous variables were categorized | N/A |
|         | | (c) If relevant, consider translating estimates of relative risk into absolute risk for a meaningful time period | N/A |
| Other analyses | 17 | Report other analyses done—eg analyses of subgroups and interactions, and sensitivity analyses | 11 Appendix p.12, 13 |
| Discussion | | Key results | 18 | Summarise key results with reference to study objectives | 13 |
|         | Limitations | 19 | Discuss limitations of the study, taking into account sources of potential bias or imprecision. Discuss both direction and magnitude of any potential bias | 15, 16, 17 |
|         | Interpretation | 20 | Give a cautious overall interpretation of results considering objectives, limitations, multiplicity of analyses, results from similar studies, and other relevant evidence | 14, 15 |
|         | Generalisability | 21 | Discuss the generalisability (external validity) of the study results | 17 |
| Other information | | Funding | 22 | Give the source of funding and the role of the funders for the present study and, if applicable, for the original study on which the present article is based | 20 |

*Give information separately for exposed and unexposed groups.
Table S3. Classifications of active physical comorbidities

| All active physical comorbidities | Active physical comorbidities at risk of COVID-19 complications according to INSPQ [6] | Active physical comorbidities at risk of COVID-19 complications according to NACI [34] |
|----------------------------------|------------------------------------------------------------------------------------------|------------------------------------------------------------------------------------------|
| Diabetes                         | Diabetes                                                                                 | Diabetes                                                                                 |
| Chronic heart disease            | Chronic heart disease                                                                     | Chronic heart disease                                                                     |
| Chronic liver disease            | Chronic liver disease                                                                     | Chronic liver disease                                                                     |
| Chronic renal disease            | Chronic renal disease                                                                     | Chronic renal disease                                                                     |
| Alzheimer disease or any other dementia | Alzheimer disease or any other dementia                                                   | Alzheimer disease or any other dementia                                                   |
| Chronic lung disease             | Chronic lung disease                                                                     | Cancer                                                                                   |
| Cancer                           | Cancer                                                                                   | Immunosuppressing condition                                                              |
| Immunosuppressing condition      | Immunosuppressing condition                                                              | Immunosuppressing condition                                                              |
| Neurologic disease               | Neurologic disease                                                                       | Neurologic disease                                                                       |
| Hematologic disease              | Hematologic disease                                                                       | Hematologic disease                                                                       |
| Thyroid disease                  | Hypothyroidism                                                                            | Hypothyroidism                                                                            |
| Arrhythmia                       | Arrhythmia                                                                               | Arrhythmia                                                                               |
| Vascular disease                 | Vascular disease                                                                          | Vascular disease                                                                          |
| Hypertension                     | Hypertension                                                                              | Hypertension                                                                              |
| Physical disability              | Paralysis                                                                                 | Physical disability                                                                       |
| Chronic inflammatory disease     |                                                                                          | Physical disability                                                                       |
| Asplenia or hyposplenia          |                                                                                          | Asplenia or hyposplenia                                                                   |
| Arthritis or arthrosis           |                                                                                          | Arthritis or arthrosis                                                                   |
| Dermatological disease           |                                                                                          | Dermatological disease                                                                   |
| Multisystemic disease            |                                                                                          | Multisystemic disease                                                                    |
| Endocrine disease                |                                                                                          | Endocrine disease                                                                        |
| Digestive disease                |                                                                                          | Digestive disease                                                                        |
| Lymphatic disease                |                                                                                          | Lymphatic disease                                                                        |
| Back or spinal condition         |                                                                                          | Back or spinal condition                                                                 |
| Other chronic pain               |                                                                                          | Other chronic pain                                                                       |
| Sensory disability               |                                                                                          | Sensory disability                                                                       |
| Infectious disease               |                                                                                          | Infectious disease                                                                       |
| Sexually transmitted and blood-borne infections | Sexually transmitted and blood-borne infections                                             | Sexually transmitted and blood-borne infections                                             |
| Orthopedic condition             |                                                                                          | Orthopedic condition                                                                     |
| Migraine                         |                                                                                          | Migraine                                                                                 |
| Vertigo or Meniere's disease     |                                                                                          | Vertigo or Meniere's disease                                                             |

INSPQ: Institut national de santé publique du Québec
NACI: National Advisory Committee on Immunization
Table S4. Sample size calculations

A) Detectable differences* for different scenarios† of proportion of individuals with comorbidities, sample size, design effect, and mean number of contacts among individuals with comorbidities

| % with comorbidities | Sample size | Design effect¥ | Mean number of contacts among individuals with comorbidities | \(n\) | \(\text{Diff} \times 100\) | \(\text{Power} \times 100\) |
|----------------------|-------------|----------------|-------------------------------------------------------------|-----|----------------|----------------|
|                     |             | Diff | Power | Diff | Power | Diff | Power | Diff | Power | Diff | Power | Diff | Power | Diff | Power | Diff | Power |
| 22%                  | 400         | 0.4  | 82    | 0.7  | 87    | 0.6  | 82    | 1.0  | 85    | 1.1  | 83    | 1.6  | 81    | 1.7  | 80    | 2.0  | 68    |
| 22%                  | 800         | 0.3  | 88    | 0.5  | 89    | 0.4  | 82    | 0.7  | 87    | 0.7  | 83    | 1.1  | 83    | 1.1  | 83    | 1.6  | 81    |
| 22%                  | 1200        | 0.3  | 97    | 0.4  | 88    | 0.4  | 94    | 0.6  | 90    | 0.6  | 88    | 0.9  | 85    | 0.8  | 80    | 1.3  | 83    |
| 35%                  | 100         | 0.8  | 86    | 1.2  | 83    | 1.2  | 84    | 1.7  | 80    | 2.0  | 76    | 2.0  | 53    | 2.0  | 47    | 2.0  | 30    |
| 35%                  | 200         | 0.5  | 83    | 0.8  | 82    | 0.8  | 86    | 1.2  | 83    | 1.3  | 80    | 2.0  | 82    | 2.0  | 76    | 2.0  | 53    |

* Differences of up to 2.0 were considered in power calculations. When a power greater than 80% could not be achieved with the maximum value of 2.0, the power for that difference is presented.
† Scenarios with proportion of 22% with comorbidities and \(n=400, 800, 1200\) represent sample sizes observed for all adults and adults aged 18 to 65 years, and scenarios with proportion of 35% with comorbidities and \(n=100, 200\) represent sample sizes observed for adults aged over 65 years.
¥ The design effect represents the inflation in variance between the observed variance in our study compared to the theoretical variance of a Poisson distribution with simple random sampling.

B) Observed design effects for comparisons of contacts between individuals with and without comorbidities*

|                      | Total contacts | Contacts at home with household members | Contacts with visitors at home and contacts in other locations |
|----------------------|----------------|----------------------------------------|-------------------------------------------------------------|
|                      | Pre-COVID      | During pandemic                        | Pre-COVID                                                  | During pandemic |
| All adults           | 11.2           | 5.1 to 9.5                             | 1.2                                                       | 0.7 to 1.3     |
| 18-65 years old      | 19.1           | 7.7 to 12.4                            | 1.5                                                       | 0.7 to 1.1     |
| >65 years old        | 2.9            | 2.0 to 9.9                             | 0.9                                                       | 0.6 to 2.1     |

* Based on comparisons of contacts presented in Table S6.
### Table S5. Key socio-demographic characteristics of participants, by period

|                      | Pre-COVID | 1st wave | Summer 2020 and 2nd wave | 3rd wave |
|----------------------|-----------|----------|--------------------------|----------|
|                      |           | All participants | with active physical comorbidities | All participants | with active physical comorbidities | All participants | with active physical comorbidities | All participants | with active physical comorbidities | All participants | with active physical comorbidities |
|                      | N        | %weighted     | N        | %weighted     | N        | %weighted     | N        | %weighted     | N        | %weighted     | N        | %weighted     |
| Total                | 792      | 203 589      | 413      | 100 313      | 4125     | 851 3274     | 1296     | 287 1009     |
| Age                  |           |               |           |               |           |               |           |               |           |               |           |               |
| 18-25 yrs old        | 95 10.9  | 5 1.4        | 90 14.1   | 53 11.8      | 53 12.0   | 38 3.6       | 494 14.2 | 185 11.7      | 18 4.5     | 167 13.8     |           |               |
| 26-45 yrs old        | 197 35.3 | 32 26.8      | 165 38.2  | 181 34.0     | 1369 34.4 | 193 21.6     | 1176 37.9 | 457 34.2      | 92 29.1    | 365 35.8     |           |               |
| 46-65 yrs old        | 294 33.0 | 87 39.4      | 207 30.8  | 129 32.8     | 1610 33.3 | 414 39.5     | 1196 31.6 | 470 32.5      | 106 32.2   | 364 32.6     |           |               |
| 66-75 yrs old        | 159 12.6 | 60 19.2      | 99 10.4   | 45 12.6      | 535 12.5  | 167 18.1     | 368 10.9  | 162 12.4      | 62 20.6    | 100 9.9      |           |               |
| >75 yrs old          | 47 8.3   | 19 13.3      | 28 6.6    | 5 8.8        | 79 7.9    | 39 17.2      | 40 5.4   | 22 9.3        | 9 13.6     | 13 8.0       |           |               |
| **Sex**              |           |               |           |               |           |               |           |               |           |               |           |               |
| Male                 | 350 50.1 | 91 49.4      | 259 50.3  | 169 49.1     | 2018 49.8 | 413 47.8     | 1605 50.4 | 577 50.2      | 127 51.3   | 450 49.9     |           |               |
| Female               | 442 49.9 | 112 50.6     | 330 49.7  | 244 50.9     | 2107 50.2 | 438 52.2     | 1669 49.6 | 719 49.8      | 160 48.7   | 559 50.2     |           |               |
| **Region**           |           |               |           |               |           |               |           |               |           |               |           |               |
| Greater Montreal1    | 407 62.6 | 103 62.1     | 304 62.7  | 293 64.3     | 2356 61.2 | 486 62.8     | 1870 60.7 | 749 61.1      | 168 59.5   | 581 61.5     |           |               |
| Other Quebec regions | 377 37.5 | 99 37.9      | 278 37.3  | 120 35.8     | 1766 38.8 | 365 37.2     | 1401 39.3 | 545 38.9      | 119 40.5   | 426 38.5     |           |               |
| **Missing**          | 8 1.0    | - 0.0        | 7 1.0     | - 0.0        | 3 0.7     | - 0.0        | 3 0.7    | 2 0.2         | - 0.0      | 2 0.2        |           |               |
| **Household size**   |           |               |           |               |           |               |           |               |           |               |           |               |
| 1                    | 236 30.0 | 72 35.6      | 164 28.2  | 124 29.9     | 1007 24.7 | 252 30.5     | 755 23.1  | 328 27.4      | 77 29.3    | 251 26.9     |           |               |
| 2                    | 389 43.1 | 107 45.9     | 282 42.2  | 182 45.5     | 2086 49.3 | 473 55.7     | 1613 47.5 | 624 47.1      | 156 52.5   | 468 45.5     |           |               |
| 3                    | 87 10.9  | 15 10.3      | 72 11.1   | 41 9.3       | 488 11.9  | 58 6.1       | 430 13.5  | 173 12.6      | 29 9.2     | 144 13.7     |           |               |
| 4+                   | 80 16.0  | 9 8.2        | 71 18.5   | 66 15.4      | 544 14.2  | 68 7.7       | 476 15.9  | 171 12.9      | 25 9.1     | 146 14.0     |           |               |
| **Education Level**  |           |               |           |               |           |               |           |               |           |               |           |               |
| No diploma, degree   | 64 7.8   | 23 10.7      | 41 6.9    | 20 5.1       | 172 4.1   | 44 4.7       | 128 3.9   | 45 3.5        | 10 4.1     | 35 3.3       |           |               |
| Secondary (high) school | 120 14.4 | 28 15.1      | 92 14.1   | 56 14.5      | 561 39.9  | 118 13.8     | 443 14.0  | 153 11.0      | 32 9.8     | 121 11.4     |           |               |
| College, CEGEP, university or other certificate/diploma | 608 77.8 | 152 74.2 | 456 79.0 | 337 80.5 | 3392 82.0 | 689 81.5 | 2703 82.1 | 1098 85.5 | 245 86.2 | 853 85.3 |
| **Main occupation**  |           |               |           |               |           |               |           |               |           |               |           |               |
| Student employed or unemployed | 76 10.8 | 6 3.2        | 70 13.3   | 51 10.4      | 481 11.1  | 47 4.9       | 434 12.8  | 153 10.3      | 22 7.2     | 131 11.2     |           |               |
| Employed or semi-retired | 363 49.5 | 61 33.7      | 302 54.8  | 230 50.6     | 2435 56.6 | 431 45.7     | 2004 59.5 | 766 55.7      | 143 44.4   | 623 59.1     |           |               |
| Temporarily not working or seeking work | 18 2.6 | 6 4.0        | 12 2.1    | 59 12.4      | 266 5.9   | 75 7.5       | 191 5.5   | 94 6.4        | 25 7.5     | 69 6.1       |           |               |
| Unemployed or retired | 335 37.1 | 130 59.2     | 205 59.8  | 73 26.6      | 943 26.5  | 298 41.9     | 645 22.2  | 283 27.7      | 97 40.9    | 186 23.7     |           |               |
| Type of comorbidities | Pre-COVID | 1st wave | Summer 2020 and 2nd wave | 3rd wave |
|-----------------------|-----------|----------|--------------------------|---------|
|                       | All participants | With active physical comorbidities | Without active physical comorbidities | All participants | With active physical comorbidities | Without active physical comorbidities | All participants | With active physical comorbidities | Without active physical comorbidities |
|                       | N | %weighted | N | %weighted | N | %weighted | N | %weighted | N | %weighted | N | %weighted | N | %weighted | N | %weighted | N | %weighted |
| Chronic lung disease  | 41 | 19.4 | -- | -- | -- | -- | -- | -- | -- | -- | -- | -- | -- | -- | -- | -- | -- | -- |
| Diabetes              | 54 | 23.7 | -- | -- | -- | -- | -- | -- | -- | -- | -- | -- | -- | -- | -- | -- | -- | -- |
| Chronic inflammatory disease | 35 | 16.7 | -- | -- | -- | -- | -- | -- | -- | -- | -- | -- | -- | -- | -- | -- | -- | -- |
| Hypertension          | 25 | 10.7 | -- | -- | -- | -- | -- | -- | -- | -- | -- | -- | -- | -- | -- | -- | -- | -- |
| Chronic heart disease | 29 | 14.6 | -- | -- | -- | -- | -- | -- | -- | -- | -- | -- | -- | -- | -- | -- | -- | -- |
| Cancer                | 19 | 9.6 | -- | -- | -- | -- | -- | -- | -- | -- | -- | -- | -- | -- | -- | -- | -- | -- |
| Thyroid disease       | 10 | 6.5 | -- | -- | -- | -- | -- | -- | -- | -- | -- | -- | -- | -- | -- | -- | -- | -- |
| Neurologic disease    | 14 | 5.4 | -- | -- | -- | -- | -- | -- | -- | -- | -- | -- | -- | -- | -- | -- | -- | -- |
| Arthritis and arthrosis | 16 | 8.3 | -- | -- | -- | -- | -- | -- | -- | -- | -- | -- | -- | -- | -- | -- | -- | -- |
| Others                | 36 | 19.5 | -- | -- | -- | -- | -- | -- | -- | -- | -- | -- | -- | -- | -- | -- | -- | -- |

Pre-COVID: February 1st 2018 to March 17th 2019; 1st wave: April 21st to May 25th 2020; Summer 2020 and 2nd wave: July 3rd 2020 to March 20th 2021; 3rd wave: March 21st to July 4th 2021.

* Greater Montreal: Regions of Montreal, Laval, Montérégie, Lanaudière, Laurentides

* Type of employment: among 18-65-year-olds employed or temporarily not working
Table S6. Time trends in the mean number of social contacts of individuals with and without active physical comorbidities

A) Total contacts

|                      | Pre-COVID n=792 | 1st wave n=413 | Summer 2020 n=679 | 2nd wave before holidays n=1261 | Holidays n=1197 | 2nd wave after holidays n=988 | 3rd wave n=1296 |
|----------------------|-----------------|----------------|-------------------|---------------------------------|----------------|-------------------------------|-----------------|
|                      | mean 95% CI     | mean 95% CI    | p<sup>¥</sup>     | mean 95% CI                     | p<sup>¥</sup>   | mean 95% CI                   | p<sup>¥</sup>   |
| All adults' Total    |                 |                |                   |                                 |                |                               |                 |
| Without comorbidities| 7.6 (6.9-8.3)   | 2.9 (2.5-3.3)  | <.001             | 4.3 (3.7-4.8)                   | <.001          | 3.6 (3.3-3.9)                 | 0.05            |
| With comorbidities   | 8.1 (7.3-9.0)   | 2.7 (2.2-3.2)  | <.001             | 4.3 (3.6-5.0)                   | <.001          | 3.9 (3.5-4.3)                 | 0.38            |
| Diff (p-value)       | -2.0 (0.008)    | 0.5 (0.23)     | -0.1 (0.92)       | -1.0 (<.001)                    | 0.2 (0.41)     | -0.3 (0.30)                   | -0.4 (0.27)     |
| 18-65 years old' Total|                |                |                   |                                 |                |                               |                 |
| Without comorbidities| 8.9 (8.0-9.9)   | 3.3 (2.6-3.9)  | <.001             | 4.4 (3.8-5.0)                   | 0.009          | 4.2 (3.8-4.7)                 | 0.66            |
| With comorbidities   | 9.3 (8.2-10.4)  | 3.2 (2.5-3.9)  | <.001             | 4.3 (3.6-5.0)                   | 0.02           | 4.5 (4.0-5.0)                 | 0.66            |
| Diff (p-value)       | -1.6 (0.16)     | 0.3 (0.76)     | 0.7 (0.40)        | -1.2 (0.003)                    | 0.1 (0.84)     | -1.0 (0.03)                   | -0.6 (0.34)     |
| >65 years old' Total |                 |                |                   |                                 |                |                               |                 |
| Without comorbidities| 3.5 (3.0-4.0)   | 1.2 (0.7-1.6)  | <.001             | 2.8 (1.9-3.7)                   | 0.002          | 1.5 (1.3-1.8)                 | 0.008           |
| With comorbidities   | 4.0 (3.3-4.8)   | 1.0 (0.3-1.7)  | <.001             | 3.3 (1.8-4.7)                   | 0.006          | 1.8 (1.5-2.0)                 | 0.05            |
| Diff (p-value)       | -1.2 (0.006)    | 0.3 (0.49)     | -1.2 (0.13)       | -0.8 (<.001)                    | -0.1 (0.78)    | 0.1 (0.87)                    | -0.0 (0.93)     |

Pre-COVID: February 1<sup>st</sup> 2018 to March 17<sup>th</sup> 2019; 1<sup>st</sup> wave: April 21<sup>st</sup> to May 25<sup>th</sup> 2020; Summer 2020: July 3<sup>rd</sup> to August 22<sup>nd</sup> 2020; 2<sup>nd</sup> wave: August 23<sup>rd</sup> 2020 to March 20<sup>th</sup> 2021; Holidays: December 17<sup>th</sup> 2020 to January 8<sup>th</sup> 2021; 3<sup>rd</sup> wave: March 21<sup>st</sup> to July 4<sup>th</sup> 2021.

<sup>¥</sup> p: p-value of the difference with the preceding period

<sup>†</sup> Results for all adults and 18-65-year-olds are adjusted for age

<sup>‡</sup> Diff: Difference between individuals with and without comorbidities and p-value of this difference
## B) Contacts at home with household members

|                      | Pre-COVID n=792 | 1st wave n=413 | Summer 2020 n=679 | 2nd wave before holidays n=1261 | Holidays n=1197 | 2nd wave after holidays n=988 | 3rd wave n=1296 |
|----------------------|-----------------|----------------|-------------------|---------------------------------|----------------|-----------------------------|-----------------|
|                      | mean 95% CI     | mean 95% CI    | mean 95% CI       | mean 95% CI                     | mean 95% CI    | mean 95% CI                 | mean 95% CI     |
| **All adults**       |                 |                |                   |                                 |                |                             |                 |
| Total                | 0.9 (0.8-1.0)   | 0.9 (0.8-1.1)  | 0.33              | 0.9 (0.8-1.0)                   | 0.80           | 1.0 (0.9-1.0)               | 0.21            |
| Without comorbidities| 0.9 (0.8-1.0)   | 0.9 (0.8-1.0)  | 0.43              | 0.9 (0.8-1.0)                   | 0.80           | 1.0 (1.0-1.1)               | 0.04            |
| With comorbidities   | 0.9 (0.8-1.0)   | 1.0 (0.7-1.2)  | 0.57              | 1.0 (0.8-1.1)                   | 0.99           | 0.9 (0.9-1.1)               | 0.31            |
| Diff (p-value)       | 0.0 (0.61)      | 0.1 (0.69)     | -0.1 (0.03)       | -0.1 (0.70)                     | 0.0 (0.40)     | 0.0 (0.72)                  |                 |
| **18-65 years old**  |                 |                |                   |                                 |                |                             |                 |
| Total                | 1.0 (0.9-1.1)   | 1.0 (0.9-1.1)  | 0.63              | 1.0 (0.9-1.1)                   | 0.71           | 1.1 (1.0-1.1)               | 0.10            |
| Without comorbidities| 1.0 (0.9-1.1)   | 1.1 (1.0-1.2)  | 0.24              | 1.0 (0.9-1.1)                   | 0.23           | 1.1 (1.0-1.2)               | 0.08            |
| With comorbidities   | 1.0 (0.8-1.2)   | 0.8 (0.7-1.0)  | 0.13              | 1.0 (0.9-1.2)                   | 0.09           | 1.0 (0.9-1.2)               | 0.83            |
| Diff (p-value)       | 0.0 (0.96)      | -0.3 (0.008)   | -0.1 (0.38)       | -0.1 (0.50)                     | 0.0 (0.09)     | 0.0 (0.76)                  |                 |
| **>65 years old**    |                 |                |                   |                                 |                |                             |                 |
| Total                | 0.4 (0.3-0.5)   | 0.6 (0.3-0.8)  | 0.37              | 0.5 (0.4-0.7)                   | 0.87           | 0.6 (0.5-0.7)               | 0.69            |
| Without comorbidities| 0.4 (0.3-0.5)   | 0.3 (0.1-0.5)  | 0.58              | 0.5 (0.3-0.8)                   | 0.25           | 0.7 (0.6-0.8)               | 0.21            |
| With comorbidities   | 0.5 (0.4-0.6)   | 0.8 (0.4-1.2)  | 0.15              | 0.6 (0.4-0.8)                   | 0.34           | 0.4 (0.2-0.6)               | 0.22            |
| Diff (p-value)       | 0.1 (0.32)      | 0.5 (0.04)     | -0.3 (0.01)       | -0.1 (0.99)                     | 0.0 (0.65)     | 0.1 (0.59)                  |                 |

**Pre-COVID:** February 1st 2018 to March 17th 2019; **1st wave:** April 21st to May 25th 2020; **Summer 2020:** July 3rd to August 22nd 2020; **2nd wave:** August 23rd 2020 to March 20th 2021; **Holidays:** December 17th 2020 to January 8th 2021; **3rd wave:** March 21st to July 4th 2021.

¥: Results for all adults and 18-65-year-olds are adjusted for age

diff: Difference between individuals with and without comorbidities and p-value of this difference
C) Contacts with visitors at home and contacts in other locations

|                      | Pre-COVID n=792 | 1st wave n=413 | Summertime 2020 n=679 | 2nd wave before holidays n=1261 | Holidays n=1197 | 2nd wave after holidays n=988 | 3rd wave n=1296 |
|-----------------------|-----------------|----------------|------------------------|-----------------------------|----------------|-----------------------------|-----------------|
| **All adults**        |                 |                |                        |                             |                |                             |                 |
| **Total**             | 6.8 (6.1-7.5)   | 2.0 (1.7-2.3)  | 3.3 (2.8-3.8) <.001   | 2.6 (2.3-2.9) 0.02         | 1.9 (1.7-2.1) <.001 | 2.2 (2.0-2.5) 0.05 | 3.4 (3.1-3.8)  <.001 |
| Without comorbidities | 7.3 (6.4-8.2)   | 1.8 (1.4-2.2)  | 3.4 (2.7-4.0) <.001   | 2.8 (2.5-3.2) 0.17         | 1.8 (1.6-2.1) <.001 | 2.3 (1.9-2.6) 0.03 | 3.5 (3.1-3.9)  <.001 |
| With comorbidities    | 5.3 (4.0-6.5)   | 2.1 (1.6-2.6)  | 3.2 (2.5-3.8) 0.009   | 2.0 (1.7-2.3) 0.002        | 2.0 (1.6-2.3) 0.95 | 2.1 (1.7-2.5) 0.74 | 3.1 (2.5-3.7)  0.005 |
| Diff (p-value)        | -2.1 (0.008)    | 0.3 (0.29)     | -0.2 (0.68)          | -0.8 (<.001)             | 0.2 (0.44)        | -0.2 (0.40)         | -0.5 (0.23)     |
| **18-65 years old**   |                 |                |                        |                             |                |                             |                 |
| **Total**             | 8.0 (7.0-8.9)   | 2.2 (1.6-2.8)  | 3.4 (2.8-4.0) 0.006   | 3.1 (2.7-3.6) 0.42        | 2.0 (1.7-2.4) <.001 | 2.5 (2.1-3.0) 0.06 | 4.0 (3.5-4.4)  <.001 |
| Without comorbidities | 8.3 (7.2-9.4)   | 2.1 (1.4-2.8)  | 3.3 (2.7-4.0) 0.01    | 3.3 (2.8-3.8) 0.99        | 2.0 (1.6-2.4) <.001 | 2.7 (2.2-3.2) 0.03 | 4.1 (3.5-4.6)  <.001 |
| With comorbidities    | 6.7 (4.7-8.7)   | 2.7 (1.2-4.2)  | 3.9 (2.5-3.8) 0.23    | 2.2 (1.6-2.8) 0.03        | 2.1 (1.3-2.9) 0.89 | 1.8 (1.1-2.6) 0.56 | 3.5 (2.5-4.5)  0.007 |
| Diff (p-value)        | -1.6 (0.17)     | 0.6 (0.51)     | 0.6 (0.47)            | -1.1 (0.004)             | 0.2 (0.74)        | -0.9 (0.06)          | -0.6 (0.33)     |
| **>65 years old**     |                 |                |                        |                             |                |                             |                 |
| **Total**             | 3.1 (2.6-3.6)   | 0.6 (0.3-0.9)  | 2.2 (1.4-3.0) <.001   | 0.9 (0.7-1.2) 0.003       | 0.7 (0.4-0.9) 0.09 | 0.9 (0.6-1.2) 0.17 | 1.6 (1.2-2.1)  0.01 |
| Without comorbidities | 3.6 (2.9-4.4)   | 0.7 (0.1-1.2)  | 2.8 (1.5-4.0) 0.003   | 1.1 (0.8-1.4) 0.01        | 0.7 (0.4-1.0) 0.05 | 0.9 (0.5-1.4) 0.37 | 1.7 (1.1-2.3)  0.05 |
| With comorbidities    | 2.3 (1.8-2.8)   | 0.5 (0.3-0.8)  | 1.5 (0.8-2.1) 0.006   | 0.6 (0.3-0.9) 0.02        | 0.6 (0.4-0.9) 0.98 | 0.9 (0.5-1.4) 0.22 | 1.6 (0.9-2.2)  0.11 |
| Diff (p-value)        | -1.3 (0.004)    | -0.2 (0.59)    | -1.3 (0.07)           | -0.5 (0.02)              | -0.1 (0.76)       | 0.0 (0.97)          | -0.1 (0.83)     |

Pre-COVID: February 1st 2018 to March 17th 2019; 1st wave: April 21st to May 25th 2020; Summer 2020: July 3rd to August 22nd 2020; 2nd wave: August 23rd 2020 to March 20th 2021; Holidays: December 17th 2020 to January 8th 2021; 3rd wave: March 21st to July 4th 2021.

1 p: p-value of the difference with the preceding period
2 Results for all adults and 18-65-year-olds are adjusted for age
3 Diff: Difference between individuals with and without comorbidities and p-value of this difference
**Table S7. Time trends in the mean total number of social contacts of individuals with and without active physical comorbidities at risk of COVID-19 complications**

A) According to INSPQ

|                        | Pre-COVID n=792 | 1<sup>st</sup> wave n=413 | Summer 2020 n=679 | 2<sup>nd</sup> wave before holidays n=1261 | Holidays n=1197 | 2<sup>nd</sup> wave after holidays n=988 | 3<sup>rd</sup> wave n=1296 |
|------------------------|-----------------|-----------------------------|-------------------|-------------------------------------------|----------------|------------------------------------------|---------------------------|
|                        | mean 95% CI     | mean 95% CI                  | mean 95% CI       | mean 95% CI                               | mean 95% CI    | mean 95% CI                               | mean 95% CI               |
| **All adults**         |                 |                             |                   |                                           |                 |                                          |                           |
| Without comorbidities  | 7.9 (7.1-8.7)   | 2.8 (2.3-3.3)                | <.001             | 4.4 (3.7-5.0)                             | <.001          | 2.9 (2.6-3.1)                             | <.001                     |
| With comorbidities     | 6.3 (4.7-7.8)   | 3.0 (2.4-3.7)                | <.001             | 3.7 (3.1-4.3)                             | 0.11           | 2.8 (2.4-3.1)                             | 0.44                      |
| Diff (p-value)         | -1.6 (0.06)     | 0.2 (0.68)                  |                   | -0.7 (0.14)                               | -0.8 (0.002)   | -0.1 (0.74)                               | -0.2 (0.55)               |
| **18-65 years old**    |                 |                             |                   |                                           |                 |                                          |                           |
| Without comorbidities  | 9.1 (8.1-10.1)  | 3.4 (2.7-4.1)                | <.001             | 4.5 (3.8-5.2)                             | 0.03           | 3.2 (2.8-3.6)                             | <.001                     |
| With comorbidities     | 8.0 (5.3-10.7)  | 2.6 (1.1-4.1)                | 0.001             | 3.9 (3.0-4.9)                             | 0.13           | 2.6 (1.9-3.2)                             | 0.10                      |
| Diff (p-value)         | -1.0 (0.48)     | -0.8 (0.32)                 |                   | -0.6 (0.35)                               | -1.0 (0.02)    | -0.6 (0.09)                               | -0.8 (0.12)               |
| **>65 years old**      |                 |                             |                   |                                           |                 |                                          |                           |
| Without comorbidities  | 3.8 (3.2-4.5)   | 1.0 (0.3-1.7)                | <.001             | 3.2 (2.0-4.5)                             | 0.003          | 1.3 (1.0-1.6)                             | 0.06                      |
| With comorbidities     | 2.9 (2.4-3.4)   | 1.3 (0.8-1.8)                | <.001             | 1.8 (1.1-2.5)                             | 0.28           | 1.1 (0.7-1.5)                             | 0.11                      |
| Diff (p-value)         | -1.0 (0.02)     | 0.3 (0.47)                  |                   | -1.4 (0.05)                               | -0.6 (0.03)    | -0.1 (0.65)                               | 0.1 (0.84)                |

INSQP: Institut national de santé publique du Québec

**Pre-COVID:** February 1<sup>st</sup> 2018 to March 17<sup>th</sup> 2019; 1<sup>st</sup> wave: April 21<sup>st</sup> to May 25<sup>th</sup> 2020; Summer 2020: July 3<sup>rd</sup> to August 22<sup>nd</sup> 2020; 2<sup>nd</sup> wave: August 23<sup>rd</sup> 2020 to March 20<sup>th</sup> 2021; Holidays: December 17<sup>th</sup> 2020 to January 8<sup>th</sup> 2021; 3<sup>rd</sup> wave: March 21<sup>st</sup> to July 4<sup>th</sup> 2021.

<sup>†</sup>p: p-value of the difference with the preceding period

<sup>†</sup> Results for all adults and 18-65-year-olds are adjusted for age

<sup>‡</sup>Diff: Difference between individuals with and without comorbidities and p-value of this difference
### B) According to NACI

|                        | Pre-COVID n=792 | 1st wave n=413 | Summer 2020 n=679 | 2nd wave before holidays n=1261 | Holidays n=1197 | 2nd wave after holidays n=988 | 3rd wave n=1296 |
|------------------------|----------------|----------------|-------------------|-------------------------------|----------------|--------------------------------|----------------|
|                        | mean ± 95% CI   | mean ± 95% CI   | mean ± 95% CI     | mean ± 95% CI                 | mean ± 95% CI  | mean ± 95% CI                   | mean ± 95% CI   |
| All adults*            |                |                |                   |                               |                |                                |                |
| Without comorbidities  | 7.9 (7.1-8.7)  | 2.9 (2.5-3.4)  | <.001             | 4.3 (3.8-4.9)                 | 3.7 (3.4-4.0)  | 2.8 (2.6-3.1)                  | 3.3 (3.0-3.6)   |
| With comorbidities     | 5.1 (4.1-6.1)  | 2.7 (2.2-3.2)  | <.001             | 3.1 (2.4-3.7)                 | 2.8 (2.3-3.2)  | 3.0 (2.5-3.4)                  | 2.8 (2.1-3.5)   |
| Diff† (p-value)        | -2.8 (<.001)   | -0.2 (0.52)    |                   | -1.3 (0.004)                  | -0.9 (0.001)   | 0.1 (0.61)                     | -0.5 (0.19)     |
| 18-65 years old*       |                |                |                   |                               |                |                                |                |
| Without comorbidities  | 9.1 (8.1-10.1) | 3.4 (2.7-4.0)  | <.001             | 4.5 (3.8-5.1)                 | 4.3 (3.9-4.8)  | 3.1 (2.8-3.5)                  | 3.8 (3.3-4.2)   |
| With comorbidities     | 5.9 (3.8-8.1)  | 1.2 (0.9-1.6)  | <.001             | 3.4 (2.0-4.9)                 | 2.6 (1.9-3.4)  | 2.8 (2.0-3.7)                  | 2.0 (1.5-2.6)   |
| Diff† (p-value)        | -3.2 (0.008)   | -2.1 (<.001)   |                   | -1.0 (0.19)                   | -1.7 (<.001)   | -0.3 (0.50)                    | -1.7 (<.001)    |
| >65 years old          |                |                |                   |                               |                |                                |                |
| Without comorbidities  | 3.7 (3.1-4.3)  | 1.2 (0.7-1.8)  | <.001             | 3.0 (2.0-4.0)                 | 1.5 (1.3-1.8)  | 1.3 (1.0-1.5)                  | 1.6 (1.2-2.0)   |
| With comorbidities     | 3.0 (2.3-3.6)  | 1.0 (0.4-1.7)  | <.001             | 1.4 (0.5-2.3)                 | 1.3 (0.6-2.0)  | 1.1 (0.7-1.5)                  | 1.4 (1.0-1.9)   |
| Diff† (p-value)        | -0.7 (0.10)    | -0.2 (0.69)    |                   | -1.6 (0.02)                   | -0.2 (0.53)    | -0.2 (0.52)                    | -0.2 (0.62)     |

NACI: National Advisory Committee on Immunization
Pre-COVID: February 1st 2018 to March 17th 2019; 1st wave: April 21st to May 25th 2020; Summer 2020: July 3rd to August 22nd 2020; 2nd wave: August 23rd 2020 to March 20th 2021; Holidays: December 17th 2020 to January 8th 2021; 3rd wave: March 21st to July 4th 2021.

† p: p-value of the difference with the preceding period
* Results for all adults and 18-65-year-olds are adjusted for age
† Diff: Difference between individuals with and without comorbidities and p-value of this difference
Table S8. Vaccination coverage with one dose of individuals with and without active physical comorbidities in the third wave

| Age Group | Without Comorbidities | With Comorbidities | Diff† (p-value) |
|-----------|-----------------------|--------------------|----------------|
| 18-25 yrs old n=199 | 44.0 (36.6-51.4) | 25.4 (3.8-47.0) | -18.6 (0.11) |
| 26-45 yrs old n=492 | 52.0 (46.7-57.1) | 57.9 (47.7-68.2) | 6.0 (0.31) |
| 46-65 yrs old n=511 | 67.6 (62.9-72.3) | 66.5 (57.7-75.2) | -1.1 (0.83) |
| >65 yrs old n=192 | 89.1 (80.1-98.0) | 93.8 (89.0-98.5) | 4.7 (0.36) |

*Diff: Difference between individuals with and without comorbidities and p-value of this difference

Third wave: March 21st to July 4th 2021.
Table S9. Recommended Quebec priority groups for vaccination against COVID-19 [14]

| Priority order | Groups                                                                 |
|----------------|------------------------------------------------------------------------|
| 1              | Elderly people living in long-term care facilities (nursing homes, CHSLD) |
| 2              | Health care workers                                                    |
| 3              | Elderly people living in retirement homes                              |
| 4              | Isolated and remote communities                                        |
| 5              | Adults aged over 80 years                                              |
| 6              | Adults aged 70 to 79 years                                             |
| 7              | Adults aged 60 to 69 years                                             |
| 8              | Adults aged under 60 years with comorbidities at risk of COVID-19 complications* |
| 9              | Adults aged under 60 years without comorbidities working in essential services |
| 10             | General adult population                                               |
| 11             | Children                                                               |

* In practice, only individuals aged under 60 years with conditions at very high risk of COVID-19 complications (hospitalised patients with comorbidities or outpatients with severe immunosuppressive conditions) were invited to be vaccinated before other individuals in their age group [48].
Table S10. Mean total number of social contacts in the third wave of individuals with and without active physical comorbidities according to vaccination status with one dose

| Age Group       | 18-25 yrs old | 26-45 yrs old | 46-65 yrs old | >65 yrs old |
|-----------------|---------------|---------------|---------------|------------|
|                 | n=199         | n=492         | n=511         | n=192      |
|                 | n  | mean  | 95% CI  | n  | mean  | 95% CI  | n  | mean  | 95% CI  | n  | mean  | 95% CI  |
| Not vaccinated  |    |       |         |    |       |         |    |       |         |    |       |         |
| Without comorbidities | 101 | 4.9  | (2.8-7.0) | 189 | 4.6  | (3.3-5.9) | 129 | 3.3  | (1.8-4.7) | 11 | 2.8  | (0.9-4.6) |
| With comorbidities            | 14  | 10.7 | (4.9-16.5) | 41  | 2.9  | (1.7-4.1) | 40  | 1.7  | (0.0-3.8) | 7  | 2.0  | (1.2-2.8) |
| Vaccinated              |    |       |         |    |       |         |    |       |         |    |       |         |
| Without comorbidities | 80  | 7.5  | (4.6-10.5) | 206 | 6.9  | (5.4-8.4) | 264 | 4.8  | (3.8-5.9) | 108| 2.1  | (1.5-2.7) |
| With comorbidities | 4   | 6.0  | (0.7-11.2) | 56  | 5.9  | (3.7-8.0) | 78  | 5.2  | (2.9-7.5) | 66 | 2.1  | (1.4-2.7) |
| Between group differences | |       |         |    |       |         |    |       |         |    |       |         |
| Not vaccinated:          |    |       |         |    |       |         |    |       |         |    |       |         |
| with – without comorbidities (p-value) | 5.8 | (0.05) |     | -1.7 | (0.03) |     | -1.6 | (0.10) |     | -0.7 | (0.46) |     |
| Vaccinated:              |    |       |         |    |       |         |    |       |         |    |       |         |
| with – without comorbidities (p-value) | -1.6 | (0.60) |     | -1.0 | (0.42) |     | 0.3  | (0.78) |     | -0.0 | (0.98) |     |
| Without comorbidities:  |    |       |         |    |       |         |    |       |         |    |       |         |
| vaccinated – not vaccinated (p-value) | 2.6 | (0.21) |     | 2.2  | (0.05) |     | 1.6  | (0.13) |     | -0.7 | (0.47) |     |
| With comorbidities:     |    |       |         |    |       |         |    |       |         |    |       |         |
| vaccinated – not vaccinated (p-value) | -4.7 | (0.25) |     | 3.0  | (0.02) |     | 3.5  | (0.06) |     | 0.1  | (0.92) |     |

Third wave: March 21st to July 4th 2021.
Results are adjusted for the time periods (March, April, May, June-July).
**Figure S1. Distribution of participants according to classifications of comorbidities**

| Category                                      | Percentage   |
|-----------------------------------------------|--------------|
| Total of 6628 adults participants             |              |
| 2 missing values                              |              |
| 4829 without comorbidities                    |              |
| 1797 with comorbidities                       |              |
| 303 without active comorbidities              |              |
| 1494 with active comorbidities                |              |
| 53 with active mental health conditions        |              |
| 1441 with active physical comorbidities (category for the main analysis) |  
| 360 excluded from the INSPQ classification     |              |
| 1081 with INSPQ active physical comorbidities  |              |
| 642 excluded from the NACI classification      |              |
| 439 with NACI active physical comorbidities    |              |

INSPQ: Institut national de santé publique du Québec
NACI: National Advisory Committee on Immunization
Figure S2. Time trends in vaccination coverage with one dose of individuals with and without active physical comorbidities in the third wave.

Third wave: March 21st to July 4th, 2021.
Example of questions S1. Questions on health conditions

27. A) Which of the following long-term conditions do you have or have had? (check all that apply)

| Health conditions                                                                                     |   |
|--------------------------------------------------------------------------------------------------------|---|
| □ Chronic lung disease (e.g., asthma, chronic bronchitis, emphysema, chronic obstructive pulmonary    | □ |
| disease (COPD), cystic fibrosis)                                                                        | Chronic renal disease and/or dialysis |
| □ Diabetes                                                                                             | □ Asplenia or hyposplenia (absent or defective spleen) |
| □ Chronic heart disease                                                                                 | □ Neurologic problem (e.g., Guillain-Barré syndrome, multiple sclerosis) |
| □ Chronic liver disease                                                                                 | □ Hematologic problem (e.g., anemia, hemoglobinopathy, bleeding problems) |
| □ Chronic inflammatory disease (e.g., lupus erythematosus, rheumatoid arthritis, psoriasis, eczema,    | □ Alzheimer disease or any other dementia |
| Crohn's disease, ulcerative colitis)                                                                    | □ Another long-term health condition, specify: |
| □ Cancer                                                                                               |   |
| □ Immunosuppressing condition (e.g., organ transplantation, HIV-infection, cancer chemotherapy,     |   |
| radiotherapy, congenital immunodeficiency)                                                             |   |
27. B) For which of the following conditions have you had any symptoms or taken any medicine in the past 12 months?

| Health conditions |  |
|-------------------|---|
| ☐ Chronic lung disease (e.g., asthma, chronic bronchitis, emphysema, chronic obstructive pulmonary disease (COPD), cystic fibrosis) | ☐ Chronic renal disease and/or dialysis |
| ☐ Diabetes | ☐ Asplenia or hyposplenia (absent or defective spleen) |
| ☐ Chronic heart disease | ☐ Neurologic problem (e.g., Guillain-Barré syndrome, multiple sclerosis) |
| ☐ Chronic liver disease | ☐ Hematologic problem (e.g., anemia, hemoglobinopathy, bleeding problems) |
| ☐ Chronic inflammatory disease (e.g., lupus erythematosus, rheumatoid arthritis, psoriasis, eczema, Crohn’s disease, ulcerative colitis) | ☐ Alzheimer disease or any other dementia |
| ☐ Cancer | ☐ Another long-term health condition, specify: |
| ☐ Immunosuppressing condition (e.g., organ transplantation, HIV-infection, cancer chemotherapy, radiotherapy, congenital immunodeficiency) | ☐ No symptoms and no medicine for these conditions in the past 12 months |
Example of questions S2. Example of the social contact diary

**DATE DAY 1**

List of persons with whom you have been in contact during this first day, from 5 am today to 5 am tomorrow morning.

| Initials or nickname | Age (or age group) of the contacted person | Sex | Person's relation with yourself | Place of contact (check all that apply) | Total duration of contact with the person | Did you touch his/her skin? | How often do you have contact with this person in general? | Ethnicity of this person |
|----------------------|-------------------------------------------|-----|---------------------------------|----------------------------------------|----------------------------------------|---------------------------|------------------------------------------------|-------------------------|
|                      |                                           |     |                                 |                                        |                                        |                           |                                                             |                         |
|                      |                                           |     |                                 |                                        |                                        |                           |                                                             |                         |
|                      |                                           |     |                                 |                                        |                                        |                           |                                                             |                         |
|                      |                                           |     |                                 |                                        |                                        |                           |                                                             |                         |
|                      |                                           |     |                                 |                                        |                                        |                           |                                                             |                         |
|                      |                                           |     |                                 |                                        |                                        |                           |                                                             |                         |
|                      |                                           |     |                                 |                                        |                                        |                           |                                                             |                         |
|                      |                                           |     |                                 |                                        |                                        |                           |                                                             |                         |
|                      |                                           |     |                                 |                                        |                                        |                           |                                                             |                         |
|                      |                                           |     |                                 |                                        |                                        |                           |                                                             |                         |